About Neelima Vidula, MD

Neelima Vidula, M.D. is a breast medical oncologist at Massachusetts General Hospital (MGH). She strives to provide outstanding patient care, and incorporate the latest data and newest therapies in treatment plans for patients. Dr. Vidula completed medical school and residency in internal medicine at Northwestern University in Chicago, IL, and a clinical and research fellowship in hematology and medical oncology at the University of California San Francisco in San Francisco, CA.

Dr. Vidula is the principal investigator of many early phase clinical trials studying novel agents for patients with breast cancer. Among these trials, she is the national co-principal investigator of a multi-center study she designed with immunotherapy and chemotherapy for chest wall disease, which she is leading at multiple sites across the country including MGH through the Translational Breast Cancer Research Consortium. She was recently awarded a prestigious Pfizer ASPIRE award for a study she designed to evaluate a PARP inhibitor in patients with somatic BRCA mutant metastatic breast cancer. Dr. Vidula also performs clinical research evaluating the impact of biomarkers on therapy response and patient outcomes, and conducts research in precision medicine using cell-free DNA and tumor genotyping. She has presented her research at several national and international meetings and published articles in high-impact journals. She also enjoys teaching medical students, residents, and fellows.

Departments, Centers, & Programs:

Clinical Interests:



Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130

Medical Education

  • MD, Northwestern University Feinberg School of Medicine
  • Residency, McGaw Medical Center
  • Fellowship, UC San Francisco Medical Center

American Board Certifications

  • Hematology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Ongoing Clinical Trials:

-Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease (NCT03095352)


-Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial (NCT03990896)


-Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer (OPERA) (NCT03326102)


-Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC) (NCT03742349)



Reviews: Comments and Ratings